Priser
Platform
Blog
Om os
Download
Akeso
Akeso
Xetra
0

Om

Akeso Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative, therapeutic solutions for the treatment of various diseases, particularly relating to oncology and autoimmune disorders. As a key player in the pharmaceutical industry, Akeso Inc. specializes in creating bi-specific antibody drugs designed to target and inhibit specific pathogenic pathways, thereby improving clinical outcomes for patients. The company is recognized for its commitment to leveraging cutting-edge technology in the development of its diverse product pipeline.

Headquartered in Zhongshan, China, Akeso Inc. operates in a market that is increasingly pivotal in addressing unmet medical needs across the globe. Its dedication to advancing therapeutic options is complemented by collaborative efforts with global partners and research institutions, enhancing its ability to bring novel drugs from concept to market. Akeso Inc.'s role in the healthcare sector underscores its importance not only in driving scientific innovation but also in impacting the future of global health solutions with potential breakthroughs in medical treatment.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I AKESO MED ENDAVU: Køb Akeso ($4RY) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Akeso, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker4RY
Land
Kina
Antal medarbejdere3.761
Hjemmesideakesobio.com
SektorSundhed
IndustriBioteknologi